- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03563365
The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol
A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream With Resveratrol , Replenix Power of Three Cream With Resveratrol With Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, Utilized to Treat Subjects With Facial Acne Vulgaris
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acne vulgaris is a common skin problem which can be challenging to treat. Enhancing the efficacy and tolerability of treatment regimens can enhance compliance and outcomes thereby potentially decreasing the morbidities associated with acne vulgaris.
The present study is designed to assess the ability of Power of 3 with resveratrol to improve efficacy and tolerability of an existing combination acne medication.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Yardley, Pennsylvania, United States, 19067
- Yardley Dermatology Associates, PC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of Acne vulgaris
- On the face, ≥ 20 non-inflammatory lesions (i.e., open and closed comedones) AND < 75 inflammatory lesions (i.e., papules and pustules) AND ≤ 1 nodulocystic lesions (i.e., nodules and cysts).
- Investigator's Global Assessment (IGA) of acne severity grade 2 or 3
- Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
- Subject/Guardian must sign an IRB-approved Informed Consent/Assent/Assent Form including photography consent, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed
Exclusion Criteria:
- Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
Subjects who have acne conglobata, acne fulminans and secondary acne (e.g.:
chloracne and drug induced acne).
- Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.
- History of hypersensitivity or allergy to benzoyl peroxide or adapalene and or any of the study product ingredients.
- Subjects who have a severe or intense irritation on the face.
- Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
- Use for less than 3 months prior to baseline (Randomization) of estrogens or oral contraceptives; use of such therapy is allowed if it will remain constant throughout the study.
- Use on the face within 1 month prior to baseline (Randomization) or during the study of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
- Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oralretinoids, which require a 6-month washout), or 5) systemic anti- inflammatory agents.
- Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.
- Subjects who have had general anesthesia for any reason and patients who have received neuromuscular blocking agents within 14 days prior to study entry (Randomization).
- Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
- Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
- Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.
- Concomitant use of tanning booths or sunbathing.
- A significant medical history of or are currently immunocompromised
- Have any systemic or dermatologic disease that may affect the evaluation of study results.
- Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or antibiotic-associated colitis.
- Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Replenix
Replenix power of 3 cream with Resveratrol applied twice daily
|
Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
|
Experimental: Replenix and Adapalene and Benzoyl Peroxide gel
Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
|
Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
FDA approved topical agent for the treatment of acne
|
Active Comparator: Adapalene and Benzoyl Peroxide gel
Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
|
FDA approved topical agent for the treatment of acne
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator Global Assessment (IGA)
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change in Acne Vulgaris on a scale of 1 to 4, where 1 represents clear skin and 4 represents severe acne, at each scheduled visit with the use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Subject Global Assessment (SGA)
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change in Acne Vulgaris on a scale of 1 to 5, where 1 represents a worsening of acne and 5 represents clearing of acne, at each scheduled visit as compared to baseline with the use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Subject Overall Assessment of Tone and Texture (SOATT)
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Investigator Overall Assessment of Tone and Texture (IOATT)
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Subject Assessment of Skin Dysesthesia (SDA)
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change in Dysesthesia on a scale of 1 to 7, where 1 represents no dysesthesia and 7 represents severe dysesthesia, at each scheduled visit with use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Subject Quality of Life (SQOL)
Time Frame: Screening, Baseline, Week 12
|
To assess the change in Subject Quality of Life on a scale of 1 to 7, where 1 represents better quality of life and 7 represents worse quality of life, at Screening, Baseline and week 12 with use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 12
|
Local Tolerability Assessment
Time Frame: Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
To assess the change in Local Tolerability on a scale of 0 to 3, where 0 represents no tolerability issues and 3 represents severe tolerability issues, at each scheduled visit with use of Replenix Power of three with Resveratrol.
|
Screening, Baseline, Week 2, Week 4, Week 8, Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard G Fried, MD, PhD, Yardley Dermatology Associates, PC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Platelet Aggregation Inhibitors
- Protective Agents
- Dermatologic Agents
- Antioxidants
- Benzoyl Peroxide
- Resveratrol
- Adapalene
Other Study ID Numbers
- TPX-PW3-2018-A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Nexgen Dermatologics, Inc.Unknown
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Replenix Power of 3 Cream with resveratrol
-
Universidad del Valle, ColombiaUniversidad de AntioquiaUnknownMuscle Weakness | Muscle LossColombia
-
aRigen Pharmaceuticals, Inc.UnknownHerpes Zoster | Postherpetic NeuralgiaUnited States
-
Tehran University of Medical SciencesCompletedCoronary Artery Disease | Metabolic SyndromeIran, Islamic Republic of
-
IRCCS San RaffaeleTerminatedPancreatic Cancer | Radiofrequency Ablation | Endoscopic UltrasoundItaly
-
Trustees of Dartmouth CollegeNot yet recruitingPain | Rejection | Placebo EffectUnited States
-
SCF PharmaInstitut de recherche clinique du littoral (IRCL)Recruiting
-
PINER Pastor Manfredi WineryUniversity of Buenos AiresCompletedObesity | Sarcopenia | Aging | Healthy AgingArgentina
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
US Department of Veterans AffairsIcahn School of Medicine at Mount Sinai; Alzheimer's AssociationCompletedAlzheimer's DiseaseUnited States
-
Mansoura UniversityActive, not recruitingPower Arm Canine RetractionEgypt